Podcasts about zepbound

Ten pounds in two weeks. No hunger. No craving for coffee or alcohol. This is Jeff's personal, week-by-week account of starting tirzepatide (sold as Zepbound), tracked through blood sugar, cholesterol markers, and a noticeable dimming of everyday motivation and joy. What changed in the first two weeks: appetite, weight, and energy Tracking glucose, LDL, ApoB, and other metabolic markers with a CGM and blood panels Why alcohol and coffee stopped feeling rewarding The emerging link between GLP-1s, dopamine, and the brain's reward circuitry The trade-off between appetite control and a sense of vitality or spark This episode is for anyone weighing GLP-1s for themselves, or curious what the drugs are actually like beyond the headlines. This episode was made possible by: CocoaVia:. Use code COMMUNE2026 for 25% off at CocoaVia.com LMNT: Get a free 8-count Sample Pack of LMNT's most popular drink mix flavors with any purchase at ⁠⁠drinklmnt.com/commune⁠⁠. Stemregen: Get 20% off your first order at stemregen.co/commune with the code COMMUNEPOD Vivobarefoot: Try Vivobarefoot risk-free with a 100-day return guarantee, and get 25% off your order at ⁠⁠vivobarefoot.com/commune⁠⁠. Stripes: Visit stripesbeauty.com and use the code COMMUNE20 for 20% off our entire product line.

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This week, we take a look at a couple of acronyms that are soaring in popularity and ask what their widespread adoption means for mental health. Maggie Harrison Dupré of Futurism has been following the AI space closely and has an update on lawsuits related to chatbots' culpability in numerous cases of attempted and completed suicides. She also explains some recent research about why prolonged engagement with the sycophantic computer programs can lead to spiraling out of reality. Then we're joined by Dr. Thomas Rutledge for a look at drugs like Ozempic and Zepbound. While the drugs are so new that research is slim, some psychological issues can emerge, especially related to self image and identity. He asks if food cravings and thinking about food have occupied a lot of space in your mind for years, what happens when that goes away? It's a complicated world we live in, Depresh Mode is here to help you make more sense of it. Articles by Maggie Harrison Dupré:Lawsuit: Bipolar Man Attempted Suicide After ChatGPT Poured Gasoline on His Religious DelusionsNew Paper Proposes What Really Causes AI PsychosisThese Logs of ChatGPT Allegedly Driving a Suicidal Woman to Her Death Are Deeply Disturbing Article by Thomas Rutledge:Your Brain on GLP-1s: What We're Learning About the Mental Side Thank you to all our listeners who support the show as monthly members of Maximum Fun. Check out our I'm Glad You're Here and Depresh Mode merchandise at the brand new merch website MaxFunStore.com! Hey, remember, you're part of Depresh Mode and we want to hear what you want to hear about. What guests and issues would you like to have covered in a future episode? Write us at depreshmode@maximumfun.org. Depresh Mode is on BlueSky, Instagram, Substack, and you can join our Preshies Facebook group.  Help is available right away. The National Suicide Prevention Lifeline: 988 or 1-800-273-8255, 1-800-273-TALK Crisis Text Line: Text HOME to 741741. International suicide hotline numbers available here: https://www.opencounseling.com/suicide-hotlines Help support this show and unlock bonus content! Become a member at https://maximumfun.org/joindepresh

Can you still eat at restaurants while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Absolutely.One of the biggest misconceptions about GLP-1 medications is that you have to avoid restaurants, skip vacations, or order the “healthiest” item on the menu to lose weight. The truth? Long-term success comes from learning how to navigate real life—not avoiding it.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna Beasley shares her simple, evidence-based strategy for eating out while staying true to your health goals. You'll learn how to build balanced meals, listen to your body's fullness cues, and enjoy restaurant meals without guilt, stress, or overthinking every bite.Whether you're headed to date night, a family dinner, a work lunch, or vacation, this episode will help you feel confident ordering at almost any restaurant while taking a GLP-1.In this episode, you'll learn:How to order at restaurants while taking a GLP-1A simple meal-building formula you can use almost anywhereWhy you don't need to avoid eating out to be successfulHow to prioritize protein without obsessing over caloriesWhat to do when you feel full halfway through your mealTips for reducing nausea or digestive discomfort when dining outHow to navigate appetizers, desserts, and drinks without guiltWhat to say when people comment on how much—or how little—you're eatingIf you've ever searched “What should I order on Ozempic?”, “Can I eat at restaurants on Wegovy?”, or “How do I eat out on a GLP-1?”, this episode is for you.

L'internet adore les explications simples sur l'obésité. Mangez moins, bougez plus, faites preuve de volonté. Dans cet épisode, un chirurgien bariatrique et une psychologue clinicienne expliquent pourquoi cette vision ne tient pas compte de la réalité humaine ni de la biologie. Si vous vous êtes déjà senti jugé en raison de votre poids, ou si vous vous êtes déjà reproché d'avoir repris du poids, cette conversation remplace la culpabilité par la science.Nous abordons l'obésité comme une maladie chronique influencée par la génétique, les hormones, le métabolisme, les médicaments, le stress, les mécanismes d'adaptation et un environnement rempli d'aliments peu coûteux et hyperappétents. Vous découvrirez que les interventions comme la gastrectomie en manchon et le pontage gastrique font bien plus que réduire la taille de l'estomac. Elles modifient aussi les hormones de la faim et de la satiété, notamment la ghréline et le GLP, tout en permettant de mieux comprendre des concepts comme la théorie du point d'équilibre pondéral, ainsi que les raisons pour lesquelles le corps résiste souvent à une perte de poids durable.Nous discutons également des aspects psychologiques de l'obésité, notamment l'alimentation émotionnelle, le bruit alimentaire, la stigmatisation liée au poids, les changements d'identité après la chirurgie et les raisons pour lesquelles mesurer le succès uniquement avec le chiffre sur la balance peut devenir contre-productif. Vous découvrirez aussi des stratégies concrètes, comme prioriser les protéines et les fibres pour favoriser la satiété et réduire la faim, ainsi que des approches réalistes pour bâtir des habitudes durables.Enfin, nous parlons des médicaments agonistes du GLP, 1, comme Wegovy, Ozempic, Mounjaro et Zepbound. Nous expliquons leur rôle dans le traitement de l'obésité, pourquoi ils sont souvent mal compris et pourquoi les meilleurs résultats sont obtenus lorsqu'ils sont combinés à des changements durables des habitudes de vie et à un suivi régulier.Si cette conversation vous a été utile, abonnez-vous, laissez un avis et partagez cet épisode avec une personne qui pourrait bénéficier d'une vision plus compatissante et fondée sur les données scientifiques de l'obésité.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting  the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules 

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

REPLAY! Bariatric surgery is the most effective tool for lasting weight loss, and her experience performing thousands of procedures has given Dr. Betsy Dovec a clear understanding of what can help patients succeed.In this episode of Wellness Junkies, host Amy Sherman sits down with Dr. Dovec, a top female bariatric surgeon and founder of BodyByBariatrics, to break down the decision between bariatric surgery vs GLP-1 medications from the perspective of someone who treats patients with both options every day. Dr. Dovec explains what gastric bypass surgery involves, why some patients go home the same day, and who may be an ideal candidate.The conversation then turns to GLP-1 weight loss medications. Amy and Dr. Dovec compare Ozempic and Zepbound, the often-overlooked side effects, and explain why weight regain is common after patients stop taking these medications. Dr. Dovec also shares why some post-surgery patients respond well to GLP-1 medications and how the combination may help support their long-term results.For women in midlife, this episode examines how GLP-1 medications may fit into treatment for weight gain during perimenopause and menopause. Dr. Dovec explains why the habits you once relied on may become less effective as your hormones shift. She also discusses the health risks associated with visceral fat and the potential role of GLP-1 treatment in reducing the internal fat linked to heart attacks, strokes, and fatty liver disease.If you have tried every diet and still feel stuck, this conversation about bariatric surgery and GLP-1 medications offers a clearer framework for understanding your options.Episode Breakdown:00:00 Meet Bariatric Surgeon Dr. Betsy Dovec01:28 What Gastric Bypass Surgery Actually Involves04:55 Who Qualifies as a Bariatric Surgery Candidate06:30 Bariatric Surgery vs GLP-1 for Long-Term Success09:37 Why GLP-1 Medications Are a Hot Topic10:57 Semaglutide and Tirzepatide Dosing Explained13:34 Same Drug Different Label for Diabetes and Weight Loss15:54 Oral GLP-1 Pills and What Comes Next17:25 Brand-Name vs. Compounded GLP-1 Medications21:13 GLP-1 Benefits During Perimenopause and Menopause23:13 Breaking the Stigma Around GLP-1 Use27:26 Visceral Fat Differences in Men and Women30:55 Sugar, Fatty Liver, and Visceral Fat Risks32:56 How Surgery and GLP-1 Both Reduce Visceral Fat36:40 Inside the OR Surgery Time and Recovery38:38 Dr. Dovec's Beauty and Self-Care Routine48:07 Where to Find Dr. Betsy DovecConnect with Dr. Betsy Dovec:Follow Dr. Dovec on InstagramVisit the BodyByBariatrics WebsiteFollow BodyByBariatrics on TikTok⁠⁠⁠⁠For More on this Episode: Read the full show notes ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠

Few prescription drugs have generated as much excitement as the new generation of weight-loss drugs, commonly called “GLP-1” medications. You've probably heard about Ozempic, Wegovy, Zepbound, and Mounjaro, even if you don't want to lose weight.In this episode: How do these drugs work? How to deal with the sometimes-unpleasant side effects? What has the GLP-1 family of drugs been proven to do, and what could they be used for in the future? Plus, details about a new Medicare program that now covers these drugs when prescribed for weight loss for those who qualify.Not a Checkbook member? ⁠⁠⁠⁠⁠⁠Sign up for a free 30-day trial to access all of our unbiased ratings⁠⁠⁠⁠⁠⁠.

She helped spark one of the biggest health conversations of the last few years—but according to Dr. Tyna Moore, the internet completely lost the plot. The naturopathic and chiropractic doctor, metabolic health expert, and host of The Dr. Tyna Show joins us to unpack what she originally meant by "microdosing" GLP-1 medications, why severe side effects may be a sign that a dose isn't right for you, and how a nuanced conversation turned into a billion-dollar industry. Emese also shares her own experience taking Zepbound, leading to an honest discussion about whether GLP-1s are forever, who may benefit from them, and why lifestyle changes still matter. Plus, Dr. Tyna explains why your metabolism probably isn't broken, the lab markers she looks at first, how chronic stress changes your body, and why strength training is non-negotiable for women as we age. If you've ever wondered whether GLP-1s are right for you—or felt confused by the endless noise online—this episode brings the conversation back to center. A Sony Music Entertainment production.  Find more great podcasts from Sony Music Entertainment at sonymusic.com/podcasts and follow us at @sonypodcasts  To bring your brand to life in this podcast, email podcastadsales@sonymusic.com Mentioned in the Episode: Learn more about your ad choices. Visit podcastchoices.com/adchoices

Recent studies say that somewhere between 12 and 16 percent of Americans have used GLP-1s like Ozempic, Wegovy, or Zepbound. Many people who take these drugs report that the meds have fundamentally changed their relationship to food. Jason Diamond is a writer who covers food, men's fashion, and culture. Throughout his life he's had a complicated relationship with both food and medication, which played a big role in how he thought about whether or not, as a new dad, to start taking GLP-1s.  Jason's story in New York Magazine is “Eating With My Daughter and My Zepbound.” The Sporkful production team includes Dan Pashman, Emma Morgenstern, Andres O'Hara, Kameel Stanley, and Jared O'Connell. Right now, Sporkful listeners can get three months free of the SiriusXM app by going to siriusxm.com/sporkful. Get all your favorite podcasts, more than 200 ad-free music channels curated by genre and era, and live sports coverage with the SiriusXM app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Has your weight loss suddenly stopped on Ozempic, Wegovy, Mounjaro, or Zepbound?If the scale hasn't moved in weeks and you're wondering whether your GLP-1 has stopped working, you're not alone. Weight loss plateaus are one of the most common—and frustrating—parts of the GLP-1 journey.The good news? A plateau doesn't automatically mean you've done something wrong or that your medication has failed.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna explains why weight loss plateaus happen, what your body is actually doing, and the evidence-based questions she asks clients before making any changes.We'll cover:What actually counts as a weight loss plateauWhy weight loss naturally slows over timeThe difference between normal weight fluctuations and a true stallCommon reasons GLP-1 weight loss plateaus happenHow protein, hydration, fiber, sleep, stress, and movement influence progressWhy eating less isn't always the answerWhen it may be time to talk with your healthcare providerThe mindset shift that helps you move through a plateau without panicIf you've been asking yourself, “Why did my weight loss stop on Ozempic?” or “Why isn't my GLP-1 working anymore?” this episode will help you understand what may be happening and what to focus on next.

Today we're tackling one of the hottest topics in medicine, nutrition, and weight loss. GLP-1 medications.You know them by names like Ozempic, Wegovy, Mounjaro, and Zepbound. You've seen the commercials.You've heard the celebrity stories. You probably know someone taking one. Maybe you're taking one yourself.These medications have transformed the conversation around weight loss, and for many people they have been life-changing. But they've also raised some important questions. Can we naturally stimulate our own GLP-1? And now, Can fasting provide some of the same benefits?And is the future of weight management medication, lifestyle, or a combination of both? Fasting & GLP-1

Send us Fan MailCan We Prevent Muscle Loss While Taking GLP-1 Weight-Loss Drugs?GLP-1 medications like Zepbound have changed the way we treat obesity. But as more people lose significant amounts of weight, another question has emerged:What happens to your muscle?It's normal to lose some lean mass—including muscle—during weight loss. But researchers are now asking whether preserving more muscle could improve long-term health, particularly as we age.In this episode, Dr. Eeks speaks with Dr. Richard Pratley, lead author of a new randomized, double-blind, placebo-controlled clinical trial investigating whether an investigational antibody called apitegromab can help preserve lean mass in people taking tirzepatide (Zepbound).Together they discuss:• Why people lose lean mass during weight loss• What "lean mass" actually means—and why it matters• Why muscle preservation has become one of the biggest new questions in obesity medicine• How apitegromab works by blocking myostatin—a protein that acts like a brake on muscle growth• The results of the study and how much lean mass participants preserved• Why preserving lean mass doesn't automatically mean preserving strength• Whether concerns about muscle loss on GLP-1 medications have become exaggerated• The importance of resistance training and adequate protein during weight loss• Whether future obesity treatment will focus less on body weight and more on body composition• The bigger question: Are we entering an era where one medication leads to another—or is there a better path???This conversation explores one of the most interesting—and practical—questions in obesity research today: Can we lose fat without sacrificing too much muscle?Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow on X. Or Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Questions, comments? Shoot me a text.Everyone's Talking About GLP-1s... But I Think We're Missing the Bigger ConversationEverywhere you turn, someone is talking about Ozempic, Wegovy, or Zepbound.Maybe your sister is taking one.Maybe your best friend has lost weight on one.Maybe you've even caught yourself wondering..."Am I the only one who still wants to lose weight without medication?"If that's where you are, this episode is for you.This isn't an anti-GLP-1 conversation.It's a bigger conversation.We're talking about what happens when your body changes after 50, why so many women feel like "nothing works anymore," and the one thing I believe we've stopped talking about.If you've ever felt confused by your hunger, frustrated by the scale, or like your body has become a complete mystery...I want to offer you a different way to think about it.Because what if the problem isn't that your body has stopped working...What if you've just never been given the translation guide?Join Hangry to HealthyWebsite: The Simplicity of WellnessTransformation Starts Here: Schedule Your ConsultFollow Me on TikTokFollow Me on Instagram

Thought your GLP-1 medication would completely eliminate sugar cravings?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and still find yourself craving chocolate, sweets, chips, or your favorite snacks, you're definitely not alone.The truth is, cravings are much more complex than most people realize—and having cravings doesn't automatically mean your medication has stopped working.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna breaks down the science behind food cravings, explains why they can still happen while taking a GLP-1, and shares practical, evidence-based strategies to help you better understand what your body may be trying to tell you.We'll cover:Why you may still crave sugar while taking a GLP-1The difference between hunger, cravings, and food noiseHow under-eating can actually increase cravingsWhy protein matters—but isn't the entire solutionThe impact of sleep, stress, and daily habits on cravingsWhy emotional eating can still happen on a GLP-1How years of habit can influence what you craveWhen cravings may be worth discussing with your healthcare providerIf you've ever wondered, “Why am I still craving sugar on Ozempic?” or worried that cravings mean your medication has stopped working, this episode will help you understand what's actually happening—and how to respond with curiosity instead of guilt.

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

Can Medicare patients get GLP-1 medications like Wegovy and Zepbound for $50 per month through the new Medicare GLP-1 Bridge Program?In this episode, Zoe is joined by Dr. Matthew Weiner and Deidre, FNP, to break down what Medicare patients need to know about the CMS Medicare GLP-1 Bridge Program. They explain who may qualify, why Medicare Part D coverage matters, and why the process is more complicated than simply getting a prescription.Deidre walks through the eligibility requirements, including BMI, prediabetes, cardiovascular disease, uncontrolled hypertension, sleep apnea, diabetes, and fatty liver disease. She also explains why some patients may not be able to use the Bridge Program if their GLP-1 medication can already be covered through their regular Medicare Part D benefits.They also discuss the two-step prior authorization process, the $50 monthly copay, why that copay may not count toward a deductible, and why documentation for a structured nutrition and lifestyle program is required.Most importantly, the team explains what patients should realistically expect as the program rolls out, why delays and confusion are likely at first, and how Pound of Cure is preparing to help eligible Arizona patients navigate access to GLP-1 medications.

About one in eight U.S. adults say they take a GLP-1 drug, according to a poll by the Kaiser Family Foundation. And that raises a number of questions for investors. As use of drugs such as Ozempic, Wegovy and Zepbound grows, the effects are moving far beyond healthcare and into the way people eat, shop, and spend. In this episode of The Important Part, Liz Thomas sits down with Caleb Silver, editor-in-chief of Investopedia and Chief Business Editor at People Inc., to examine the rise of the “GLP-1 economy.” Together, they explore how changing consumer behavior could affect food companies, restaurants, apparel, travel, home appliances, telehealth, and the pharmaceutical industry. Liz and Caleb also discuss where new demand may emerge, which established businesses could face pressure, and what investors should watch as the GLP-1 market continues to develop. Can major brands adapt quickly enough, or will a new group of companies be built around this changing consumer? This episode is for informational purposes only and should not be considered investment or medical advice. For more, read Liz's column every Thursday at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠On The Money⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ by SoFi⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, and follow Liz on Twitter ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@LizThomasStrat⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Additional resources: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠On The Money⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Sign up for SoFi's newsletter for intel, insights, and inspo to help you get your money right. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Investing 101 Center⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: At SoFi, we believe investing is for everyone — which is why we've created a hub with info for beginners and experts alike. Start exploring to get investment education, advice, resources, and more. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Wealth Investing Guide⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: Information you need to know to make your money work harder for you. This podcast should be used for informational purposes only and not deemed as a recommendation. Our Automated investing is via SoFi Wealth LLC, and is a registered investment advisor. Our Active investing is via SoFi securities LLC, member FINRA/SIPC. For additional disclosures related to the SoFi Invest® platforms, please visit www.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ SoFi.com/Legal⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. ©2026 Social Finance, Inc. All Rights Reserved.

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Medicare's new GLP-1 Bridge Program gives eligible retirees access to Wegovy and Zepbound for $50 a month — but there are three financial catches worth knowing before you enroll.In this episode of the Secure Your Retirement Podcast, Radon and Murs discuss one of the biggest Medicare developments of 2026 — the new GLP-1 Bridge Program, launching July 1, which allows eligible Medicare beneficiaries to access popular GLP-1 weight loss medications like Wegovy and Zepbound for a flat $50 copay per month. Joined by Peace of Mind Wealth Management's in-house Medicare specialist Sean Southard, they break down exactly what this program is, who qualifies, how the approval process works, and what the financial implications look like for retirees on fixed incomes.Listen in to learn about the three financial angles every retiree needs to understand before enrolling in the GLP-1 Bridge Program, including why that $50 copay sits completely outside your normal Medicare Part D protections, what happens when the program ends in December 2027, and how GLP-1 medications and Medicare prescription drug coverage fit into a broader retirement planning conversation around healthcare costs, budgeting, and long-term affordability.In this episode, find out:What GLP-1 medications are, why Medicare historically excluded them for weight loss, and what changed in 2026 to make the GLP-1 Bridge Program possibleWho qualifies for the program based on BMI and health conditions, and how your doctor submits a prior authorization request through Medicare's centralized systemWhy the $50 flat copay does not count toward your Medicare Part D deductible or annual out-of-pocket maximum, and what that means for your retirement budgetWhat retirees need to plan for when the program's temporary status ends in December 2027 and costs could jump significantlyThe health considerations and side effects of GLP-1 medications that matter most for older adults, and why this conversation belongs with your doctor and your financial plannerTweetable Quotes:"Retirees need to avoid assuming that this benefit program is going to be permanent forever. Plan for what happens if that $50 copay jumps back up to several hundred dollars a month." — Murs Tariq"This is both a healthcare conversation and a financial planning conversation. Retirees should evaluate long-term affordability, potential future coverage changes, and how chronic disease management fits into an overall retirement plan." — Shawn SouthardResources:If you are in or nearing retirement and you want to gain clarity on what questions you should be asking, learn what the biggest retirement myths are, and identify what you can do to achieve peace of mind for your retirement, get started today by requesting our complimentary video course, Four Steps to Secure Your Retirement!To access the course, simply visit POMWealth.net/podcast.

A lot of conversations about GLP-1s focus on food noise, appetite, and weight loss.But there's another side of this that almost nobody is talking about.What happens when these medications suddenly give you the freedom to eat foods you've been afraid of your entire life?For women who have spent decades dieting, restricting, and trying to control their eating, that freedom can feel incredible. But it can also create some unintended consequences.In this episode, I'm talking about:* Why some women start relying on the medication's "guardrails" more than their own skills* Why medication can lower food noise but can't make food choices for you* The disordered eating patterns that can quietly creep back inWhether you're on a GLP-1, considering one, or simply curious about all the buzz  around these medications, this episode will give you a different lens to think about food, weight loss, and what sustainable change really requires.Connect with JordanaFind me on InstagramSign up for my weekly letter with personal stories and nutrition, body image and mindset tipsSchedule a free discovery call to talk more about working together Listen to more episodes of The Diet Diaries

Started feeling hungry again on your GLP-1 and wondering if your medication has stopped working?You're not alone.One of the biggest misconceptions about Ozempic, Wegovy, Mounjaro, and Zepbound is that you should never feel hungry. But the truth is, hunger is a normal biological signal—and experiencing hunger doesn't automatically mean your GLP-1 isn't working.In this episode, Registered Dietitian and GLP-1 expert Gianna explains why appetite can change throughout your GLP-1 journey, what influences hunger beyond your medication, and how to tell the difference between normal hunger and something that may deserve a conversation with your healthcare provider.We'll discuss:Why it's normal to feel hungry on a GLP-1Whether your medication can “stop working”The difference between hunger and food noiseCommon reasons your appetite may increaseHow under-eating can actually make hunger worseThe impact of stress, sleep, hormones, and daily routines on appetiteWhen increased hunger may be a reason to talk with your healthcare providerWhy learning to trust your body's hunger cues is part of long-term successIf you've ever worried that feeling hungry means you've failed—or that your medication isn't doing its job—this episode will help you understand what's actually happening and how to respond with confidence instead of fear.

Amy King hosts your Monday morning Wake Up Call. ABC News White House correspondent Karen Travers opens the show talking about Iran and U.S still in talks despite the latest strikes. ABC News national reporter Steven Portnoy talking about more SCOTUS rulings. Bloomberg Business correspondent Denise Pellegrini talks about Comcast planning to spin off NBC Universal, the Zepbound craze, and the peptide craze. The show closes with FOBBV Media Manager Jenny Voisard talking about the push to ban fireworks in Big Bear because of the possible effect on animals.See omnystudio.com/listener for privacy information.

Millions of Medicare beneficiaries are about to gain access to GLP-1 weight loss medications for as little as $50 per month through the new Medicare Bridge Program, launching July 1. In this episode of On The Pen, Dave Knapp sits down with obesity medicine expert Angela Fitch to break down exactly who qualifies, how to apply, which medications are covered, and what this historic expansion of obesity treatment access means for patients across America.We discuss:✅ Medicare Bridge Program eligibility requirements✅ Zepbound, Wegovy, Foundayo (orforglipron), and GLP-1 coverage updates✅ BMI and comorbidity qualifications✅ Prediabetes, sleep apnea, cardiovascular disease, and obesity treatment access✅ How Medicare patients can obtain GLP-1 medications✅ Why obesity is finally being treated as a chronic disease✅ The future of obesity medicine and Medicare coverage✅ Concerns about access to care vs access to medication✅ Muscle loss, nutrition, strength training, and healthy weight loss✅ The Treat and Reduce Obesity Act (TROA)This may be one of the most important developments in obesity treatment history, potentially opening the door for millions of Americans living with obesity, prediabetes, cardiovascular disease, and other weight-related conditions to receive evidence-based care.

Why aren't there more medical insurance plans that cover alternative medicine? Solutions for Long Covid; MK7 vitamin K slows arterial calcification; Keto diet shows promise for treatment of anorexia; It's not so much salt restriction—it's the dietary sodium/potassium ratio in hypertension; Study finds multivitamins don't keep you from getting Covid—but when you get it, it's milder; Incidence of social anxiety disorder is soaring among young people.

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What if Medicare finally made GLP-1 medications for weight management more affordable — could this be the moment that changes access for millions of people?Today, we're talking about something that's been years in the making in the world of obesity care: the expanded coverage of anti-obesity medications for patients on Medicare. Starting July 1st, eligible Medicare beneficiaries have a real opportunity to access GLP-1 receptor agonist medications at a much more affordable monthly cost through a new federal program — and for many patients, this could mark a major shift in access to treatment that's historically been limited or completely out of reach under Medicare's coverage rules.This change didn't happen overnight. It comes after years of advocacy, policy discussions, and ongoing efforts to get obesity recognized as a chronic medical condition that deserves treatment just like any other disease. In this episode, we break down where this program came from, how it connects to the bigger picture of obesity care, who it applies to, and everything you need to know about eligibility, covered medications, and how the process actually plays out in real life.Topics discussed:How the Bridge Program Could Expand Access to Obesity MedicationsFor the First Time, Medicare Is Opening the Door to Obesity MedicationsThe BMI and Health Condition CriteriaWhy the Reason for Your Prescription Matters Just as MuchThe Details That Make a Real Difference — Prior BMI and Lifestyle SupportThe List of Weight Loss Medications Covered by the Bridge ProgramWant the full breakdown? This episode covers all the details on eligibility, covered medications, and what this program could mean for you or someone you love navigating Medicare and obesity treatment. Find it wherever you get your podcasts — and if it helps, share it with someone who might need to hear it too.Resources mentioned in this episode:GLP-1 Prescribers Guide — CMSMedicare GLP-1 Bridge Program Details — CMSConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

What happens when GLP-1 medications stop working the way you hoped they would? In this mailbag episode, Dr. Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction. From the dangers of under-fueling to why individualized treatment matters so much, this conversation unpacks the science behind weight resistance with clarity and compassion.Key TakeawaysWhy fasting and restrictive eating may worsen metabolic adaptationThe real role insulin plays in metabolic healthHow PCOS and lipedema complicate weight loss treatmentWhy some people plateau on GLP-1 medications over timeThe importance of fueling, muscle preservation, and individualized careLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

What is GLP-1 microdosing, and can smaller doses of medications like Ozempic, Wegovy, and Zepbound lead to better long-term weight loss results?In this episode, registered dietitian Zoe is joined by Deidre, FNP, to break down one of the biggest conversations in obesity medicine right now: GLP-1 microdosing. They explain how microdosing differs from standard manufacturer dosing, why FDA-approved dosing schedules are designed for clinical trials, and why a one-size-fits-all approach may not work for every patient.Deidre explains how slower, smaller dose increases may help reduce side effects like nausea and abdominal discomfort, while still supporting hunger control, fewer cravings, less food noise, and gradual weight loss. They also discuss super responders, non-responders, compounded medications, and why personalized GLP-1 dosing can make a major difference in long-term maintenance.They also unpack the debate around GLP-1 microdose marketing, including the recent dispute involving Eli Lilly, Noom, and tirzepatide, and what it means for patients navigating telehealth weight loss programs.Most importantly, Zoe and Deidre explain why medications are only one part of obesity treatment. Sustainable weight loss still depends on nutrition, whole foods, protein, fiber, lifestyle changes, and long-term support.

A few years ago, I came across a quote that said:"I think the key to a happy life as an adult woman is to channel your inner weird little girl and make her happy."It immediately resonated with me.I was the kid making potions in the yard, obsessed with magic books, fortune tellers, mood rings, crystals, and all things mystical. And the older I get, the more I realize those parts of me never disappeared—they just got buried under adulthood and responsibility.In this episode, I'm talking about whimsy—not as a trend, but as a way of reconnecting with yourself. I'm sharing what's on my whimsical summer list, why I've been intentionally making more room for wonder, and how this connects to one of the core principles of Irresistible You: Feed Your Soul.Because maybe creating a magical life isn't about becoming someone new.Maybe it's about remembering who you've been all along. ✨

ABC's Jim Ryan joins Arizona’s Morning News to talk about the new black market for next-gen diet drugs like Wegovy and Zepbound. People are so eager to try them that they’ll jump the gun on FDA approvals. 

This episode explores how to use GLP-1 medications like semaglutide/Ozempic and tirzepatide/Mounjaro safely and effectively. Dr. Mike Hart and Dr. Christle Guevarra Do discuss once-weekly dosing, individualized titration, optimal dose selection, food noise, appetite suppression, and the risks of dosing mistakes with vials or gray-market peptides. They also cover why resistance training, protein, fiber, and realistic nutrition habits are essential for preserving muscle and maintaining results. The conversation expands into GLP-1 benefits beyond weight loss, including cardiovascular protection, inflammation, autoimmune flares, addiction-related behaviors, alcohol cravings, libido, menstrual cycles, PCOS, sleep apnea, and what to expect when stopping the medication. Dr. Christle Guevarra Do is a physician focused on obesity medicine, GLP-1 education, weight management, and sustainable lifestyle change. Drawing from both her clinical experience and her own long-term use of GLP-1 medication, she helps patients understand how these medications fit into the bigger picture of long-term health. Her approach emphasizes individualized care, strength training, nutrition, behavior change, and realistic maintenance strategies rather than quick fixes. In this episode, she shares practical guidance for using GLP-1s responsibly while protecting muscle, managing hunger, and building habits that support lasting results. Dr. Christle Guevarra Website https://www.drchristle.com/ Dr. Christle's Free GLP-1 Guide https://www.drchristle.com/glp1-guide Dr. Christle Instagram https://www.instagram.com/dr.christle/ Ozempic — semaglutide https://www.ozempic.com/ Wegovy — semaglutide for weight management https://www.wegovy.com/ Mounjaro — tirzepatide https://mounjaro.lilly.com/ Zepbound — tirzepatide for weight management / sleep apnea https://zepbound.lilly.com/ FDA: Concerns With Unapproved GLP-1 Drugs https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss Retatrutide Clinical Trial Info https://clinicaltrials.gov/study/NCT05882045 Vyvanse — lisdexamfetamine https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad Creatine — NIH Supplement Info https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ Psyllium Husk / Fiber — MedlinePlus https://medlineplus.gov/druginfo/meds/a601104.html Berberine — NCCIH https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know Tesamorelin — MedlinePlus https://medlineplus.gov/druginfo/meds/a611035.html CJC-1295 — PubMed Research https://pubmed.ncbi.nlm.nih.gov/16352683/ Ipamorelin — PubMed Research https://pubmed.ncbi.nlm.nih.gov/9849822/ FDA: Peptides / Compounding Safety Concerns https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks Oura Ring https://ouraring.com/ White Claw https://www.whiteclaw.com/   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:45 Weekly Dosing Debate 03:41 Starting Dose Basics 06:28 Pens vs Vials Safety 08:37 Finding Your Sweet Spot 11:01 Nighttime Binge Window 13:32 Lifestyle Work Still Matters 14:30 Benefits Beyond Weight 17:27 Libido and Low Calories 22:26 Alcohol Hits Different 24:59 Cancer Claims Reality Check 26:59 Strength Training Priority 29:06 Supplements and Creatine 29:38 Creatine Protein Fiber Basics 31:50 Berberine Pros and Cons 32:37 Peptides Sleep and Muscle 35:28 Too Lean for GLP-1 38:52 Cycles PCOS and Fertility 40:45 Food Noise vs Appetite 44:42 Staying On or Stopping 49:19 Heart Rate and HRV Concerns 51:38 Ozempic vs Mounjaro Choices 54:45 Sleep Apnea and Wrap Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

What Really Happens Inside an Obesity Clinic GLP-1 medications are everywhere right now. Patients are asking about Ozempic, Wegovy, Zepbound, compounded medications, muscle loss, “Ozempic face,” insurance denials, and what happens when the weight loss slows down.But what does obesity medicine actually look like inside the clinic? In this episode, I'm joined by Joseph Zucchi, PA-C, clinical supervisor and physician associate at Transition Medical Weight Loss in Salem, New Hampshire. This is not your typical GLP-1 conversation. We're going beyond protein goals, nausea tips, and constipation management to talk about what clinicians are really facing in practice: how to dose these medications, when to switch, and how to support patients when insurance coverage disappears.In this episode, you'll learn:What to assess when a patient hits a weight loss plateau beyond simply increasing the dose  How to talk with patients about GLP-1 concerns like muscle loss, thyroid cancer warnings, GI side effects, and “Ozempic face”  Why obesity medications are tools, not “cheating,” and how to address weight stigma in the exam room  What clinicians should know about compounded GLP-1 medications and why FDA-approval matters  How to document for prior authorizations and what insurance companies are often looking for  What happens when patients lose GLP-1 coverage and how to discuss alternative medication options  What Joe is most excited about in the future of obesity medicine, including new medications and expanding coverage If you prescribe GLP-1 medications, counsel patients on weight management, or feel overwhelmed by the insurance and documentation side of obesity medicine, this episode will give you a practical, behind-the-scenes look at what comprehensive obesity care can look like.Connect with JoeResources mentioned:Obesity Medicine Nutrition Course (with a 2026 medication update) Use code POD15 for 15% off!155 | Unstuck: Strategies for Sustainable Weight Loss151 | Are GLP-1s Masking Undiagnosed Eating Disorders?Obesity Medication InfographicAny Questions? Send Me a MessageSupport the showConnect with Colleen:InstagramLinkedInSign up for my FREE Newsletter - Nutrition hot-topics delivered to your inbox each week.Disclaimer: This podcast is a collection of ideas, strategies, and opinions of the author(s). Its goal is to provide useful information on each of the topics shared within. It is not intended to provide medical, health, or professional consultation or to diagnosis-specific weight or feeding challenges. The author(s) advises the reader to always consult with appropriate health, medical, and professional consultants for support for individual children and family situations. The author(s) do not take responsibility for the personal or other risks, loss, or liability incurred as a direct or indirect consequence of the application or use of information provided. All opinions stated in this podcast are my own and do not reflect the opinions of my employer. 

This week it's just Steven and Devon holding down the fort while Ben is away, which means the conversation somehow manages to jump from guitar maintenance to Star Wars collectibles to post-apocalyptic murder mysteries without missing a beat. Real Life Devon spent part of the week giving some attention to an old Kelly-style guitar that had been fighting him for years. After wrestling with the floating tremolo system, he explains the joys and frustrations of guitar intonation and why getting everything properly adjusted can feel more like engineering than music. With the guitar finally behaving itself, he's been spending time learning Vivaldi's Summer, proving once again that classical music can be every bit as metal as heavy metal. Meanwhile, Steven returned from a Disney trip with a collection of souvenirs that may or may not require their own dedicated shelf. The haul includes a Spira gift card, a BB-series droid, a C-series droid head popcorn bucket, a Grand Holocron, a new Star Wars font hat, and nearly every Kyber crystal available. Unfortunately, despite collecting the entire rainbow, none of the elusive secret crystals made their way home. Such is the way of the Force. Future or Now Devon dives into Paradise on Hulu, starring Sterling K. Brown. What initially appears to be a political thriller quickly reveals itself to be something much stranger. Without spoiling too much, the series combines a whodunit mystery with a post-apocalyptic setting and some surprisingly deep character development. The show's vision of "The American Dream Underground" becomes one of the most fascinating aspects of the story, and Devon argues that the character work is what truly elevates the series above similar mystery shows. The conversation also briefly touches on Hoppers, now available on Disney+. The verdict? It's definitely strange. Whether that strangeness is good or bad may depend entirely on your tolerance for Pixar-style weirdness. There may also be connections to the Pixar Theory, but there simply isn't enough time to open that particular can of worms. Steven brings an interesting study examining the real-world effects of popular GLP-1 weight-loss medications like Ozempic, Wegovy, Mounjaro, and Zepbound. Researchers analyzing Fitbit data discovered that while patients successfully lost weight after starting the medications, many also became less physically active. Daily step counts and exercise levels declined, raising concerns because these drugs can reduce muscle mass alongside fat loss. The findings highlight an important reminder: losing weight and maintaining physical fitness aren't necessarily the same thing, and preserving strength remains a critical part of long-term health. Links Paradise (IMDb): https://www.imdb.com/title/tt27444205 Weight-loss medication activity study: https://www.sciencedaily.com/releases/2026/06/260614011841.htm   This episode covers everything from guitar maintenance and Disney loot to dystopian mysteries and the surprising relationship between weight loss and physical activity. Just another normal week on Science Faction.

ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine.We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more!From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases?In this episode:✅ Survodutide obesity and liver fat reduction data✅ Mazdutide Phase 3 obesity and diabetes results✅ UBT251 triple agonist weight loss data✅ Berobenatide (MET-097) long-acting GLP-1 updates✅ CagriSema diabetes and obesity trial results✅ Zenagamtide (Amycretin) injectable and oral development✅ Petrelintide amylin agonist info✅ Future GLP-1, GIP, glucagon, and amylin therapiesThe future of obesity medicine is no longer just about who produces the most weight loss. It's about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale.Read more obesity medicine news at obesity.news

Worried about gaining weight back after Ozempic, Wegovy, Mounjaro, or Zepbound?You're not alone. One of the biggest concerns people have during their GLP-1 journey is what happens after the weight loss phase—and how to actually maintain their results long-term.In this episode, Registered Dietitian and GLP-1 expert Gianna breaks down what sustainable weight maintenance really looks like, why maintaining weight loss is different from losing weight, and the habits that support long-term success.Because keeping weight off isn't about being perfect. It's about building routines that you can realistically maintain for years to come.We're covering:Why weight maintenance is different than weight lossCommon reasons people regain weight after losing itThe role of appetite, food noise, and long-term behavior changeWhy protein and strength training matter for maintenanceHow muscle supports long-term health and weight managementThe mindset shifts that make maintenance easierWhy all-or-nothing thinking keeps people stuckWhat successful long-term maintenance actually looks likeWhether you're currently taking Ozempic, Wegovy, Mounjaro, or Zepbound—or simply thinking ahead to the future—this episode will help you focus on the habits that support lasting results.

Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

It's been impossible to keep up with tennis news lately, with Serena's return, the grass season starting, and the top players continuing to pressure the Slams on prize money and consultation. We had too much on our Roland Garros wrap agenda, so here's the twin to episode 425. We talk about Serena's long-simmering “comeback,” the product tie-ins with Ro and Zepbound, and her successful doubles match with Canadian star Victoria Mboko. We also check in with the ongoing player response to prize money increases (as a proportion of tournament revenue) and what could come next. Finally, we give our unorganized thoughts on the Rafa doc, check in with a kind Reddit user, and give you a Knicks segment that is now -- thankfully -- a time capsule of life before Jalen Brunson was an MVP and NBA champion! 1:30 The "wildfire" … was warranted  11:30 Serena and Vicky ace their first (and only) test 23:10 Is this comeback meant to be a proof of concept for GLP-1 use? 33:10 Wimbledon prize money -- will the increase be enough for “Project Red Eye?” 40:00 Netflix's Rafa documentary was a somewhat harrowing experience 49:30 Admitting I was wrong is important! 52:40 A quick Knicks segment (now a time capsule)

In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40

GLP-1 medications like Ozempic, Wegovy, and Zepbound have become some of the most talked-about treatments for weight loss, but their benefits may extend far beyond the scale. In this episode, Diana breaks down what GLP-1 medications are, how they work in the body, and what current research shows about kidney health. She explores the growing evidence for kidney protection, discusses emerging research in autosomal dominant polycystic kidney disease (ADPKD), and shares practical considerations for people with PKD who are considering semaglutide or tirzepatide medications. SHOW NOTES, REFERENCES, & TRANSCRIPTS www.thepkddietitian.com/58 Episode #57: Weight Loss & PKD: Can It Slow Kidney Growth and Disease Progression? GLP1 Clinical Trial: Glucagon-Like Peptide-1 Receptor Agonist in ADPKD FLOW Trial: https://pubmed.ncbi.nlm.nih.gov/38785209/ Support the Show: patreon.com/PKDDietitian WORK WITH DIANA: thepkddietitian.com/workwithme HAVE A QUESTION? Send a message to info@thepkddietitian.com FIND THE PKD DIETITIAN ONLINE Patreon: PKDDietitian Instagram: @The.PKD.Dietitian Facebook: The PKD Dietitian Website: thepkddietitian.com Support the show and access future bonus content and deeper PKD nutrition insights: patereon.com/PKDDietitian DISCLAIMER The PKD Dietitian Podcast is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Linktree for Community ResourcesNeed help appealing a GLP-1 Insurance Denial? FindHonestCare.com/KimRo - Telehealth for GLP1 Weight ManagementThe Absolute Lies You've Heard About GLP-1s (Ozempic Myths Debunked) [REPLAY]Are you being lied to about Ozempic, Mounjaro, and Wegovy? In this special replay episode, leading obesity medicine specialists break down the biggest GLP-1 myths taking over your feed. We are reposting this crucial conversation because it is more relevant than ever. With GLP-1 price changes and expanding access options through federal programs like the Medicare GLP-1 Bridge, understanding the real science behind these medications is essential for patient advocacy.We are sharing a few favorite replay episodes right now while Kim is away on bereavement leave following the loss of her sister. We want to deeply thank our subscribers for staying engaged and supporting the show during this time.In this episode of The Plus Sidez Podcast, Kat joins Kim to sit down with obesity medicine specialists Dr. Matea Rentea and Dr. Ali Novitzki to help listeners better understand their disease and feel empowered in their healthcare journey.The Myths We Debunk:The Muscle Loss Scare: The data behind weight loss and body composition, explaining why the medication itself is not destroying your lean mass.The Willpower Narrative: Why obesity is a genetic, chronic metabolic disease rooted in brain biology, not a failure of personal willpower.The Shot-Only Illusion: How the medication works alongside your body's natural satiety signals and gut receptors.Obesity Doctor Guidance Shared:Metabolic Protection: A practical discussion on utilizing a 10-minute fitness routine and a 100-gram protein framework to maintain lean mass and support insulin sensitivity.System Navigation: Insights on navigating insurance barriers, managing prior authorizations, and advocating for proper medical care.Mental Resilience: Tools to process unsolicited comments about your weight and protect your peace from societal judgment.Episode Topics:Why We Are Replaying This Episode: Prices, Access, and UpdatesThe Insurance Landscape: Understanding Prior AuthorizationsMeet the Obesity Medicine SpecialistsDeconstructing the GLP-1 Muscle Loss NarrativeStrategies for Protecting Your MetabolismWhat the Scales Do Not Show About Insulin ResistanceNatural Satiety Triggers and Gut ReceptorsRecognizing Obesity as a Biological Chronic DiseaseAddressing Weight Stigma and External CommentarySubscribe to The Plus Sidez Podcast for science-backed episodes breaking down metabolic health, body recomposition, and the truth about weight loss.Search TagsGLP1 lies debunked, Ozempic myths, Mounjaro weight loss journey, Wegovy truth, Zepbound body recomposition, insulin sensitivity hacks, natural GLP1 boosters, treating obesity metabolic disease, plus sidez podcast, dr matea rentea, dr ali novitzki_________________________________________________________________________Join this channel to get access to perks:https://www.youtube.com/channel/UC0HUIGKl3BN4Vg6LYI-dkOA/join_________________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovySend us Fan Mail!Support the showKim Carlos, Executive Producer TikTokInstagram Kat Carter,  Producer TikTokInstagram 

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)What If the Lowest Dose Isn't Actually the Safest Dose?If you've spent any time in weight loss or wellness spaces online, you've probably come across the term microdosing — and chances are, it was framed as the smarter, gentler, more mindful way to use GLP-1 medications. But is that actually true? That's exactly what we're digging into today.In this episode, we cover:Is "Microdosing" GLP-1s Actually a Thing? — Where the term came from, why it took off, and whether it holds up clinically.The Right Dose Is the One That's Actually Working for You — What therapeutic dosing actually means and how to know if yours is doing its job.Weight Loss Is a Side Effect, Not Always the Goal — Why the scale isn't the only thing worth tracking — and what to measure instead.There Is No Prize for the Lowest Dose — The real cost of staying subtherapeutic and why "less is more" doesn't always apply here.There is no prize for taking the lowest dose. The goal isn't to stay as low as possible, and it isn't to push as high as possible either. The goal is to find the dose that actually works for you — for your body, your health conditions, and your specific outcomes. Check out the full episode and give it a listen — it's worth your time.Connect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

Nutritionist Leyla Muedin discusses research showing simple strength tests—grip strength and a five-rep sit-to-stand chair test—predict longevity in older women. In a University at Buffalo study of over 5,000 women ages 63–99 followed for eight years, stronger grip and faster chair-stand times were linked to lower mortality; every additional 7 kg of grip strength corresponded to a 12% reduction in death risk, and faster chair-stands were also associated with improved survival, even after adjusting for activity, cardiovascular fitness, and inflammation. She emphasizes prioritizing muscle-strengthening alongside aerobic exercise and suggests accessible resistance options (weights, bodyweight moves, or household items) with professional guidance as needed. She then cites UK Biobank data linking long-term statin use to declines in grip strength and appendicular lean mass, urging discussion with physicians and added vigilance, especially for those also using GLP-1 drugs that may reduce protein intake and muscle mass.

In this episode, I'm talking honestly about weight loss burnout. The mental exhaustion that comes from constantly thinking about food, planning meals, trying to “be good,” starting over, tracking, and feeling like your body is always a project that needs fixing.I also share what this experience has been like for me while being on Tirzepatide. The food noise is quieter, but now I find myself in this strange in-between space where I'm hungry, but nothing sounds good. I take a few bites and feel full… while somehow still feeling hungry at the same time. And honestly? I'm tired.This episode isn't anti-weight loss. It's about what happens when your entire life starts revolving around shrinking yourself, and the realization that maybe peace matters too.Because you deserve a life bigger than calorie counting.Show Notes

It's in the News! The top diabetes stories and headlines happening now. Top stories this week include: Afrezza inhaled Insulin is Approved for Kids, CGM + Ketone Monitor gets European approval, Food Coloring & Diabetes Study, Device Recalls include Omnipod and Dexcom, Beta Bionics shares more about their patch pump, ADA conference info and more! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcripts: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. ADA starts this week – safe travels to those of you heading to New Orleans. We'll be covering remotely so please follow on social – make sure to Like the FB page or join the group. We've got a wrap up episode planned for this podcast as well as some indepth interviews with the newsmakers from the conference. I will see some of you next week in Chicago. We have a couple of seats left for our Club 1921 dinner on June 10th in Northbrook – this is a FREE dinner for HCPs and patient leaders – all about screening for T1D. More info on the website under the events tab. Okay.. our top story this week: XX Afrezza inhaled insulin is now approved for kids and teens. The FDA okayed MannKind's afrezza for children 6 and older with type 1 and type 2 diabetes. MannKind says its proprietary Technosphere drug delivery platform enables the rapid absorption of insulin into systemic circulation. This follows FDA approval earlier this year for an update that revises recommendations for the starting mealtime dosage when patients switch from subcutaneous mealtime insulin regimens. MannKind also completed enrollment in February for a study evaluating the initiation of Afrezza therapy shortly after type 1 diabetes diagnosis in pediatric patients.   The company said it made Afrezza available for eligible patients for $35 or less per month. Desmond Schatz, professor of pediatrics at the University of Florida College of Medicine, said: "Mealtime insulin can be especially challenging for children because eating and snacking patterns, activity levels, and daily settings like school and sports often vary. With its rapid onset and dosing at the start of a meal, Afrezza may help clinicians better match insulin therapy to how children and families live day to day, while offering a needle-free mealtime option." Lots more to come on this – we're working on a bonus episode with one of the pediatric endos who worked on the clinical trials that led to this approval – hopefully have that out later this week. https://www.massdevice.com/mannkind-fda-approval-inhaled-insulin-children/ XX FDA has agreed to consider a new drug for the treatment of adults with type 1 and chronic kidney disease. Finerenone (fy-near-uh-known) is currently approved in the US for adults with CKD associated with type 2 diabetes and for adults with heart failure with left ventricular ejection fraction of 40% or greater. Chronic kidney disease (CKD) is present in over one-third of adults with diabetes, and because it's such a serious condition, interventions are needed to reduce its incidence and help people live a long and prosperous life. https://www.docwirenews.com/post/fda-grants-priority-review-to-finerenone-snda-for-type-1-diabetes-associated-ckd XX Abbot gets European approval for the world's first dual glucose‑ketone sensing technology for people with diabetes. They're calling this Libre Duo and Libre Duo 10 Day, and it's designed to continuously measure glucose and ketone levels every minute. Abbott plans to begin launching Libre Duo systems in select European countries later this year. Libre Duo delivers up to 15 days of wear and will be offered to adults ages 18 and older. Libre Duo 10 Day offers up to 10 days of wear and is intended for people ages 2 and older. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors. https://abbott.mediaroom.com/2026-05-27-Abbott-secures-CE-Mark-for-worlds-first-dual-glucose-ketone-sensing-technology-for-people-with-diabetes   XX Huge recall for Omnipod. Insulin says a manufacturing issue through ongoing product monitoring that could result in insulin under-delivery  with specific lots of its Omnipod 5, Dash and Eros pods. Insulet said the scope of this action reaches approximately 7 million pods. This issue is separate from the March recall that affected certain Omnipod 5 lots. According to the Acton, Massachusetts-based company, some of its affected pods may have a small tear in the tubing (cannula) just above the skin. This tear lands between the pod and the point where the cannula enters the body. If this occurs, insulin may leak outside of the device instead of being fully delivered into the body as intended. This may lead to under-delivery of the therapeutic.   Individuals using an affected pod may notice wetness on the skin or pod adhesive or detect the smell of insulin. However, some cases may prove difficult to detect and go unnoticed. Of the approximately 7 million pods included in the action, approximately 60% have been consumed or are expired. The pods affected by the correction represent approximately 8.5% of the 2025 global Omnipod pod prodcution. Insulet says it has sufficient supply to replace affected pods. It expects no disruption to product availability. The company said it has notified the FDA and all other relevant regulatory authorities of its action.   The full list of affected pod lots can be found here. https://www.massdevice.com/insulet-another-omnipod-5-recall-dash-eros/ XX Dexcom is warning that certain scrapped glucose sensors have been stolen and resold. Dexcom said it has not received any reports of severe adverse events associated with the stolen product. One lot of scrapped devices carries a risk of infection for sensors that are not properly sterilized, and another lot had an elevated internal testing failure rate, meaning users would have an increased risk of having no sensor readings available. Dexcom said the affected sensors were stolen during the destruction process and then sold by third parties. The company routinely scraps sensors that do not meet its standards. The sensors are sent to a third-party vendor for destruction and recycling.   Dexcom said it traced sales of the stolen devices to Pharmsource, which is not an authorized Dexcom distributor but supplies some independent pharmacies and U.S. durable medical equipment distributors. Because of this, pharmacies that purchase products from Pharmsource should review their inventory, Dexcom said.   People with sensors from the affected lots should not use those sensors and can call customer support to request replacements. Dexcom has set up a website to help users check if their devices are affected. https://www.medtechdive.com/news/dexcom-warns-of-scrapped-glucose-sensors-being-resold/821139/ XX XX   Beta Bionics plans to debut its first insulin patch pump by the end of the second quarter of 2027, subject to Food and Drug Administration clearance. The device, called Mint, would be compatible with Beta Bionics' interoperable automated glycemic controller, a software that allows for the pump to automatically adjust insulin delivery based on readings from a glucose sensor. Beta Bionics first unveiled the prototype for Mint last year at the American Diabetes Association's Scientific Sessions. The device is expected to have a similar size and wear time, at three days, to Insulet's patch pumps on the market. It would have a 200-unit insulin reservoir.   Mint differs by containing a mix of reusable and disposable components. Beta Bionics plans to make the device exclusively available in the pharmacy channel, building on its existing agreements for its current iLet insulin pump. Beta Bionics is one of several diabetes tech companies developing patch pumps to compete with market leader Insulet. Tandem Diabetes Care and Medtronic spinoff MiniMed have also announced planned patch pumps. Tandem said it plans to file a 510(k) submission this quarter for a tubeless version of its small, durable pump, and Medtronic plans to submit its patch pump to the FDA this fall.   https://www.medtechdive.com/news/beta-bionics-to-launch-its-first-insulin-patch-pump-to-compete-with-insulet/821091/ XX CVS puts Zepbound back on it's coverage list – with it's Caremark PBM. They also added Foundayo, Lilly's obesity pill. CVS had dropped Lilly's Zepound last summer but kept competitor Wegovy. It'll be back at Caremark October first. All three of the nation's largest pharmacy ⁠benefit managers ​now cover Lilly's full obesity medicine portfolio. https://www.reuters.com/legal/litigation/cvs-brings-back-coverage-lillys-obesity-drug-zepbound-2026-05-28/   More to come, including a new benefit from metformin for women, something new from Tidepool, big news for T1D in Austalia and more.. XX A new study suggests that higher long-term exposure to food colouring additives — including both synthetic and natural colourings commonly found in processed foods and beverages — may be associated with an increased risk of developing type 2 diabetes. Researchers analyzed data from more than 108,000 adults in the French NutriNet-Santé cohort between 2009 and 2023, following participants for a median of just over eight years. During that time, 1,131 participants developed type 2 diabetes. The study found that people with the highest intake of total food colouring additives had a 38% higher risk of developing type 2 diabetes compared with non- or low-consumers.   Several specific additives were linked to increased risk, including caramel colouring additives such as total caramel (E150 family), plain caramel (E150a), sulphite ammonia caramel (E150d), and beta-carotene (E160a). Additional associations were observed for curcumin (E100), anthocyanins (E163), paprika extract (E160c), lutein (E161b), and cochineal-derived colourings (E120). "Our findings revealed positive associations between widely consumed food colouring additives and type 2 diabetes incidence," the authors wrote, adding that further research is needed to better understand the mechanisms behind the findings and whether food colouring regulations should be reevaluated. https://www.medscape.com/viewarticle/use-common-food-colours-tied-high-type-2-diabetes-risk-2026a1000hes XX Big news for Australia – their Therapeutic Goods Administration (TGA) approves Tzield. Tzield is now approved in Australia to delay the onset of stage 3 (or clinical) T1D in people aged eight years and older with stage 2 T1D – the early, pre-symptomatic stage of the condition, where changes in blood glucose levels have begun but insulin therapy is not yet required. Breakthrough T1D Australia Chief Executive Officer, Sydney Yovic, said the approval represented a transformational moment for Australians affected by T1D. https://newshub.medianet.com.au/2026/05/landmark-approval-of-tzield-in-australia-ushers-in-a-new-era-of-delay-for-type-1-diabetes/155036/ XX https://www.theatlantic.com/health/2026/05/diabetes-pregnancy/687324/ XX A common diabetes drug may hold great potential to help with aging, even if scientists aren't exactly sure why. According to a study, the drug metformin doesn't just help patients to effectively manage their type 2 diabetes. it may also give older women a better chance of living to 90. Scientists in the US and Germany used data from a long-term US study of postmenopausal women.   Records for a total of 438 people were selected – half of whom took metformin to treat diabetes, and half of whom took a different diabetes drug, sulfonylurea.   While there are some caveats and asterisks to the study, those in the metformin group were calculated to have a 30 percent lower risk of dying before the age of 90 than those in the sulfonylurea group. The study used age 90 as the marker for 'exceptional' longevity. However, scientists aren't yet sure that the drug extends lifespan, especially in humans – which is part of the reason for this study. RCTs could follow further down the line to dig deeper into these results, the researchers suggest. In the meantime, as the global population continues to skew older, studies continue to find ways to keep us healthier for longer and reduce damage to the body as we age. https://www.sciencealert.com/a-common-diabetes-drug-is-linked-with-exceptional-longevity-in-women XX The American Diabetes Association® (ADA) will host the 2026 Scientific Sessions from June 5-8 in New Orleans. The ADA's Scientific Sessions is the world's largest diabetes meeting, convening an expected audience of over 12,000 leading physicians, scientists, researchers, and healthcare professionals from around the globe. The premier diabetes meeting, which is also offered virtually, will feature the latest scientific findings in diabetes and obesity, where leading experts and peers will share findings in research for prevention, care, and cures at the Ernest N. Morial Convention Center. Key themes will include: Advancing obesity and metabolic health: Prevention, early detection, and disease modification: Improving cardiometabolic outcomes: Transforming care through innovation and access: New research will highlight how technology, artificial intelligence, and implementation strategies are reshaping diabetes care—reducing treatment burden, expanding access, and enabling more person-centered care. Advancing beta cell replacement and cure strategies: Fostering innovation: On Saturday, June 6, from 4:30-6:00 p.m., the Innovation Challenge, which debuted in 2023, invites emerging companies to pitch novel ideas to improve the lives of people living with diabetes. A panel of judges, with input from a live audience, determines which contestants will earn a private audience with potential funders. XX Tidepool, the nonprofit leader advancing innovation in diabetes technology, announced that Tidepool+ Direct Connect is now available through the Epic Showroom. Built on SMART on FHIR, Direct Connect brings interactive diabetes device data directly into Epic workflows, helping clinicians use patient data during routine care. "Tidepool has always focused on making diabetes data more accessible and actionable," said Brandon Arbiter, CEO. "We're excited to empower clinicians using Epic with insightful, intuitive patient data that fits directly into their encounter workflow so they can use it to improve care in the moment it matters."   Tidepool+ Direct Connect supports scalable deployment across Epic-enabled health systems. This architecture enables faster, more intuitive rollouts, enhancing Tidepool's existing EHR integration capabilities.   Direct Connect is part of Tidepool's ongoing work to improve how clinicians can use timely and relevant diabetes device data during patient visits to help drive better health outcomes.   The feature is now available in the Connection Hub of the Epic Showroom.   https://www.businesswire.com/news/home/20260527780274/en/Tidepool-Launches-in-Epic-Showroom-to-Bring-Diabetes-Device-Data-into-the-Point-of-Care XX

Mazel morons! This week, we're back at you with the original recipe and we're coming in hot. From millennial parents sipping Mai Tais in the dugout , to a Knicks away game and a suite full of Hasidic Jews, we're recapping our Mother's days and thoughts on etiquette across the board. Plus, we're getting real about the Zepbound blues and consulting a cheese witch to read our future in a block of cheddar. What are ya nuts? Love ya! Write us! goodguyspodcast1@gmail.com Follow us on Instagram and TikTok!  Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode. Produced by Dear Media. Learn more about your ad choices. Visit megaphone.fm/adchoices

Three new GLP-1 studies, why every food is suddenly "high protein," the Bethenny Frankel shoe drama blowing up Instagram, and why I'm on a ketamine table as you listen. Three new studies just shifted the GLP-1 conversation, and not in the direction women have been hearing about. Chalene digs into what's actually happening to muscle and bone density, why the rebound after coming off matters more than anyone's talking about, and the three questions every woman on Ozempic, Wegovy, Mounjaro, or Zepbound should bring to her next doctor's appointment. She also gets into why every grocery aisle suddenly screams "high protein," and why this whole moment is starting to feel suspiciously like the Snackwell cookie era. There's a simple protein target that works without tracking macros, and Chalene walks through how she's using it. Then she breaks down the Bethenny Frankel shoe drama that took over Instagram this week. What the shoe brand founder got wrong, what Bethenny got wrong, and the rules of brand partnerships that almost nobody outside the influencer world understands. Finally, a personal update. As you're listening to this, Chalene is on the table for another medically supervised ketamine treatment with Dr. Andrew Levinson. She shares why she went back for a third session, what the last journey taught her about control, and who this kind of work is really for.  

The vast majority of employer health plans do not cover GLP-1s for weight loss. But roughly 20% do, many believing it will help their bottom line. Perhaps when employees take Wegovy or Zepbound, they'll need less medical care tied to health issues from obesity. Today on the show, can GLP-1s save employers money in the long run?Fact checking by Sierra Juarez.Your Next Listen — No healthcare premiums? In this economy?! Here's how.— Julie Wernau's original episode with TradeoffsConnect with The Indicator — Sign up for The Indicator's brand new newsletter— Find our socials, YouTube and more!— For sponsor-free episodes, subscribe to NPR+ See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy